Neural antigen-specific autoimmune disorders

Immunological Reviews

Volumn 248, Issue 1, 2012, Pages 104-121

  Iorio, Raffaele ^a   Lennon, Vanda A ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

Autoantibodies; Paraneoplastic neurological diseases

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; AMPA RECEPTOR; AMPHIPHYSIN; ANTINUCLEAR ANTIBODY; AQUAPORIN 4; AUTOANTIBODY; BETA INTERFERON; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; EXCITATORY AMINO ACID TRANSPORTER 2; GLIAL NEURONAL NUCLEAR ANTIBODY 1; GLUTAMATE DECARBOXYLASE 65; GLYCINE RECEPTOR; IMMUNOGLOBULIN G; MA1 ANTIBODY; MA2 ANTIBODY; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURONAL NUCLEAR AUTOANTIBODY 1; NEURONAL NUCLEAR AUTOANTIBODY 2; NEURONAL NUCLEAR AUTOANTIBODY 3; NICOTINIC RECEPTOR; NOTCH LIKE EPIDERMAL GROWTH FACTOR RELATED RECEPTOR; NOTCH RECEPTOR; PERIPHERIN; PURKINJE CELL CYTOPLASMIC AUTOANTIBODY 1; PURKINJE CELL CYTOPLASMIC AUTOANTIBODY 2; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; BRAIN REGION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEMBRANE; CEREBELLAR ATAXIA; DOWN REGULATION; DYSAUTONOMIA; EATON LAMBERT SYNDROME; EFFECTOR CELL; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOHISTOLOGY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; PARANEOPLASTIC NEUROPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SEROPREVALENCE; SPINAL GANGLION; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; GANGLIA; HUMANS; NEUROMUSCULAR JUNCTION; RECEPTORS, NEUROTRANSMITTER; SYNAPTIC MEMBRANES; SYNAPTIC TRANSMISSION;

EID: 84862740239     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01144.x     Document Type: Article

References (157)

1. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715-719.
2. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50:652-657.
3. Strauss AJL, Seegal BC, Hsu KC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle binding, complement-fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med 1960;105:184-191.
4. Strauss AJ, van der Geld HW, Kemp PG Jr, Exum ED, Goodman HC. Immunological concomitants of myasthenia gravis. Ann N Y Acad Sci 1965;124:744-766.
5. Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurons in sensory carcinomatous neuropathy. Brain 1965;88:529-538.
6. Lennon VA, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;34:2106-2112.
7. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998;4:1321-1324.
8. Cross SA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003;54:38-50.
9. Darnell RB. RNA regulation in neurologic disease and cancer. Cancer Res Treat 2010;42:125-129.
10. Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995;38:102-110.
11. Vernino S, Eggenberger ER, Rogers LR, Lennon VA. Paraneoplastic neurological autoimmunity associated with ANNA-1 autoantibody and thymoma. Neurology 2002;59:929-932.
12. + T cells. J Clin Invest 2009;119:2042-2051.
13. Ueki K, Ramaswamy S, Billings SJ, Mohrenweiser HW, Louis DN. ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3. Neurogenetics 1997;1:31-36.
14. Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci USA 1998;95:13254-13259.
15. Perrone-Bizzozero N, Bolognani F. Role of HuD and other RNA-binding proteins in neural development and plasticity. J Neurosci Res 2002;68:121-126.
16. Ruggiu M, et al. Rescuing Z+ agrin splicing in Nova null mice restores synapse formation and unmasks a physiologic defect in motor neuron firing. Proc Natl Acad Sci USA 2009;106:3513-3518.
17. Luque FA, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991;29:241-251.
18. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003;53:580-587.
19. Pittock SJ, et al. Paraneoplastic jaw dystonia and laryngospasm with antinuclear autoantibody type 2 (anti-Ri). Arch Neurol 2010;67:1109-1115.
20. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001;50:301-311.
21. Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008;70:924-928.
22. Schuller M, Jenne D, Voltz R. The human PNMA family: novel neuronal proteins implicated in paraneoplastic neurological disease. J Neuroimmunol 2005;169:172-176.
23. Dalmau J, et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999;122:27-39.
24. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001;50:339-348.
25. Sakai K, Mitchell DJ, Tsukamoto T, Steinman L. Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. Ann Neurol 1990;28:692-698.
26. Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 1997;17:1406-1415.
27. Hetzel DJ, Stanhope CR, O'Neill BP, Lennon VA. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. Mayo Clin Proc 1990;65:1558-1563.
28. McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol 2011;68:1282-1289.
29. Plantone D, et al. Brainstem and spinal cord involvement in a paraneoplastic syndrome associated with anti-Yo antibody and breast cancer. J Neurol 2011;258:921-922.
30. Altermatt HJ, Rodriguez M, Scheithauer BW, Lennon VA. Paraneoplastic anti-Purkinje and type I anti-neuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. Lab Invest 1991;65:412-420.
31. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000;47:297-305.
32. de Graaff E, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; doi:10.1002/ana.23550.
33. Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol 1976;33:660-661.
34. Graus F, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol 1998;96:1-7.
35. Briani C, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011;76:705-710.
36. Horta E, McKeon A, Lennon VA, Benarroch EE. Reversible paraneoplastic tonic pupil with PCA-Tr-IgG and Hodgkin lymphoma. Neurology 2012;78:1620-1622.
37. Schmidt EF, Strittmatter SM. The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol 2007;600:1-11.
38. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-154.
39. Veyrac A, et al. CRMP5 regulates generation and survival of newborn neurons in olfactory and hippocampal neurogenic areas of the adult mouse brain. PLoS ONE 2011;6:e23721.
40. Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol 2008;63:531-534.
41. Lichte B, Veh RW, Meyer HE, Kilimann MW. Amphiphysin, a novel protein associated with synaptic vesicles. EMBO J 1992;11:2521-2530.
42. De Camilli P, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kd autoantigen of stiff-man syndrome with breast cancer. J Exp Med 1993;178:2219-2223.
43. Pittock SJ, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005;58:96-107.
44. Wessig C, Klein R, Schneider MF, Toyka KV, Naumann M, Sommer C. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003;61:195-198.
45. Geis C, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced gabaergic inhibition. Brain 2010;133:3166-3180.
46. Solimena M, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. New Engl J Med 1988;318:1012-1020.
47. Baekkeskov S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990;347:151-156.
48. Peltola J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000;55:46-50.
49. Pittock SJ, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006;81:1207-1214.
50. McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Ahlskog JE, Pittock SJ. Stiff-man syndrome & variants: clinical course, treatments & outcomes. Arch Neurol 2011;69:230-238.
51. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10:7270-7275.
52. + T cells. J Immunol 2010;184:4863-4870.
53. Eriksson KS, Zhang S, Lin L, Lariviere RC, Julien JP, Mignot E. The type III neurofilament peripherin is expressed in the tuberomammillary neurons of the mouse. BMC Neurosci 2008;9:26.
54. Oblinger MM, Wong J, Parysek LM. Axotomy-induced changes in the expression of a type III neuronal intermediate filament gene. J Neurosci 1989;9:3766-3775.
55. Chamberlain JL, et al. Peripherin-IgG association with neurologic and endocrine autoimmunity. J Autoimmun 2010;34:469-477.
56. Simpson JA. Myasthenia gravis: a new hypothesis. Scott Med J 1960;5:419-436.
57. Lennon VA, Carnegie PR. Immunopharmacological disease: a break in tolerance to receptor sites. Lancet 1971;1:630-633.
58. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic value. Neurology 1976;26:1054-1059.
59. Hohlfeld H, Wekerle H, Marx A. The immunopathogenesis of myasthenia gravis. In: Engel A ed. Myasthenia Gravis and Myasthenic Disorders. 2nd edn. Oxford: Oxford University Press, 2012:60-89.
60. Engel AG, Lambert EH, Howard FM Jr. Immune complexes (lgG and C3) at the motor end-plate in myasthenia gravis. Ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977;52:267-280.
61. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987;505:526-538.
62. Burges J, Wray DW, Pizzighella S, Hall Z, Vincent A. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 1990;13:407-413.
63. Yoshikawa H, Lennon VA. Acetylcholine receptor autoantibody secretion by thymocytes: relationship to myasthenia gravis. Neurology 1997;49:562-567.
64. Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007;36:651-658.
65. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
66. Evoli A, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311.
67. McConville J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-584.
68. Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008;63:782-789.
69. Shigemoto K, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006;116:1016-1024.
70. Kawakami Y, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011;77:1819-1826.
71. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011;69:418-422.
72. Zhang B, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69:445-451.
73. Lennon VA, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
74. Harper CM, Lennon VA. Lambert-Eaton syndrome. In: Kaminski HJ ed. Current Clinical Neurology: Myasthenia Gravis and Related Disorders. 2nd edn. New York: Humana Press, 2009:209-225.
75. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983;80:7636-7640.
76. Lambert EH, Lennon VA. Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. Muscle Nerve 1988;11:1133-1145.
77. Wu J, Lukas RJ. Naturally-expressed nicotinic acetylcholine receptor subtypes. Biochem Pharmacol 2011;82:800-807.
78. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000;343:847-855.
79. Lennon VA, Ermilov LG, Szurszewski JH, Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003;111:907-913.
80. Vernino S, Ermilov LG, Sha L, Szurszewski JH, Low PA, Lennon VA. Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci 2004;24:7037-7042.
81. McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009;66:735-741.
82. Yellen G. The voltage-gated potassium channels and their relatives. Nature 2002;419:35-42.
83. Benarroch EE. Potassium channels: brief overview and implications in epilepsy. Neurology 2009;72:664-669.
84. Gutman GA, et al. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005;57:473-508.
85. Klein CJ, et al. Insights from LGI1 and CASPR2 potassium channel-complex autoantibody subtyping. Arch Neurol; in press.
86. Hart IK, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997;41:238-246.
87. Barber PA, Anderson NE, Vincent A. Morvan's syndrome associated with voltage-gated K+ channel antibodies. Neurology 2000;54:771-772.
88. Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62:1177-1182.
89. Vincent A, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701-712.
90. Knowles CH, et al. A role for autoantibodies in some cases of acquired nonparaneoplastic gut dysmotility. Scand J Gastroenterol 2002;37:166-170.
91. Viallard JF, Vincent A, Moreau JF, Parrens M, Pellegrin JL, Ellie E. Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudoobstruction. Eur Neurol 2005;53:60-63.
92. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70:1883-1890.
93. Majoie HJ, de Baets M, Renier W, Lang B, Vincent A. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 2006;71:135-141.
94. Somers KJ, et al. Psychiatric manifestations of voltage-gated potassium-channel complex autoimmunity. J Neuropsychiatry Clin Neurosci 2011;23:425-433.
95. Geschwind MD, et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol 2008;65:1341-1346.
96. Flanagan EP, et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc 2010;85:881-897.
97. Dhamija R, et al. Neuronal voltage-gated potassium channel complex autoimmunity in children. Pediatr Neurol 2011;44:275-281.
98. Klein CJ, Lennon VA, Aston PA, McKeon A, Pittock SJ. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology; in press.
99. Lai M, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776-785.
100. Irani SR, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734-2748.
101. Ogawa Y, et al. ADAM22, a Kv1 channel-interacting protein, recruits membrane-associated guanylate kinases to juxtaparanodes of myelinated axons. J Neurosci 2010;30:1038-1048.
102. Oiso S, et al. Contactin-associated protein (Caspr) 2 interacts with carboxypeptidase E in the CNS. J Neurochem 2009;109:158-167.
103. Quek AM, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012;69:582-593.
104. Klein CJ, et al. Insights from LGI1 and CASPR2 potassium channel-complex autoantibody subtyping. Arch Neurol; in press.
105. Kalachikov S, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002;30:335-341.
106. Strauss KA, et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 2006;354:1370-1377.
107. Lachance DH, et al. An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol 2010;9:55-66.
108. Meeusen JW, et al. Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol. Ann Neurol 2012;71:417-426.
109. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
110. Lucchinetti CF, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461.
111. Roemer SF, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194-1205.
112. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012;doi:10.1177/1352458512439439.
113. Pittock SJ, et al. Neuromyelitis optica and non-organ-specific autoimmunity. Arch Neurol 2008;65:78-83.
114. McKeon A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39:87-90.
115. Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008;65:629-632.
116. Waters PJ, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
117. McKeon A, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008;71:93-100.
118. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-968.
119. Popescu BF, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011;76:1229-1237.
120. Apiwattanakul M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010;68:757-761.
121. Iorio R, et al. Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology 2011;77:1644-1646.
122. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
123. Hinson SR, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-2231.
124. Hinson SR, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008;205:2473-2481.
125. Hasegawa H, Ma T, Skach W, Matthay MA, Verkman AS. Molecular cloning of a mercurial-insensitive water channel expressed in selected water-transporting tissues. J Biol Chem 1994;269:5497-5500.
126. Jung JS, Bhat RV, Preston GM, Guggino WB, Baraban JM, Agre P. Molecular characterization of an aquaporin cDNA from bracandidate osmoreceptor and regulator of water balance. Proc Nat Acad Sci USA 1994;91:13052-13056.
127. Rash JE, Davidson KG, Yasumura T, Furman CS. Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly. Neuroscience 2004;129:915-934.
128. Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, Verkman AS. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J Biol Chem 2011;286:16516-16524.
129. Hinson SR, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 2012;109:1245-1250.
130. Vincent T, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181:5730-5737.
131. Crane JM, Bennett JL, Verkman AS. Live cell analysis of aquaporin-4 m1/m23 interactions and regulated orthogonal array assembly in glial cells. J Biol Chem 2009;284:35850-35860.
132. Bradl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.
133. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133:349-361.
134. Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011;70:943-954.
135. Lynch JW. Native glycine receptor subtypes and their physiological roles. Neuropharmacology 2009;56:303-309.
136. Shiang R, Ryan SG, Zhu YZ, Hahn AF, O'Connell P, Wasmuth JJ. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 1993;5:351-358.
137. Hutchinson M, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008;71:1291-1292.
138. Mas N, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2010;82:1399-1401.
139. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007;7:39-47.
140. Dalmau J, et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36.
141. Dalmau J, et al. Anti-NMDA receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-1098.
142. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
143. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011;77:589-593.
144. Bien CG, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012;135:1622-1638.
145. Tuzun E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 2009;118:737-743.
146. Hughes EG, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-5875.
147. Lai M, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424-434.
148. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010;50:295-322.
149. Nicoletti F, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011;60:1017-1041.
150. Faas GC, Adwanikar H, Gereau RW, Saggau P. Modulation of presynaptic calcium transients by metabotropic glutamate receptor activation: a differential role in acute depression of synaptic transmission and long-term depression. J Neurosci 2002;22:6885-6890.
151. Hildebrand ME, et al. Functional coupling between mGluR1 and Cav3.1 T-type calcium channels contributes to parallel fiber-induced fast calcium signaling within Purkinje cell dendritic spines. J Neurosci 2009;29:9668-9682.
152. Lancaster E, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011;77:1698-1701.
153. Sillevis Smitt P, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000;342:21-27.
154. Benarroch EE. GABAB receptors: structure, functions, and clinical implications. Neurology 2012;78:578-584.
155. Kaupmann K, et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 1998;396:683-687.
156. Lancaster E, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67-76.
157. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011;77:179-189.